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Abstract: Personalized medicine has finally been featured in psychiatric journals but
psychiatrists have mainly focused on the promise of using disease mechanisms to personalize
treatment. Psychiatric disorders such as schizophrenia and depression are not diseases, in the
medical sense, and are probably more like syndromes. Instead of spending much time and effort
focusing on the mechanisms of diseases that may instead be syndromes, the author believes that
psychiatrists should 1) learn more about personalizing prescription via drug mechanisms, a
pharmacological approach to personalized medicine; and 2) reconsider prior attempts by
traditional clinical psychopharmacologists to use sophisticated clinical approaches that try to
subdivide psychiatric syndromes into groups that may be more homogenous for treatment
response.
Key words: Alzheimer disease;individualized medicine; personalized medicine; personalized
prescription; pharmacogenetics; pharmacogenomics; psychiatry; psychopharmacology;
psychotropic drugs.
Summations:
-Personalized medicine has finally arrived in psychiatric journals but these journal articles have
mainly focused on the promise of using disease mechanisms to personalize treatment.
Perspectives:
-Psychiatric disorders such as schizophrenia and depression are not diseases, in the medical
sense, and are probably more like syndromes. Focusing on their disease mechanism does not
appear to be a good idea.
-Psychiatrists should learn more about personalizing prescription via drug mechanisms, a
pharmacological approach to personalized medicine.
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-Psychiatrists need to reconsider prior attempts by traditional clinical psychopharmacologists to
use sophisticated clinical approaches that try to subdivide psychiatric syndromes into groups that
may be more homogenous for treatment response.
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Personalized medicine has been a fashionable concept that has been endorsed by
pharmacological journals for almost 20 years, but has not reached psychiatric journals until more
recently. The simple idea behind this concept is that each patient is different and therefore each
individual needs to be treated differently. Everybody seems to agree that each patient is different
but there is disagreement on how to best apply this in practice; the recommendations for
implementation vary according to the background and interest of each author using the term
“personalized medicine”. This is best illustrated by the first psychiatric book (1) using this term,
written in 1952 by Osborn, a psychiatrist with a psychoanalytic approach who used it to explain
that psychiatrists should treat each patient as a unique individual according to his/her unique
psychological mechanisms. Obviously, the current approaches to personalized medicine in
psychiatry are not related to psychoanalytic theory, but the emphasis on uniqueness is shared.
This perspective article discusses how personalized medicine can be used in psychiatry,
including the approaches 1) in pharmacological journals over the last 20 years, 2) in recent
psychiatric journals, and 3) in traditional clinical psychopharmacology. First, the tradition of
personalized medicine in pharmacology was developed in the context of pharmacogenetics and
drug mechanisms (differences in drug response based on differences in drug mechanisms).
Second, psychiatric journals have recently referred to personalized medicine in the context of the
promise of biomarkers which could explain disease mechanisms in psychiatry (differences in
drug response based on differences in disease mechanisms). Third, before DSM-III nosology was
developed, psychopharmacologists traditionally classified patients in subgroups based on clinical
symptoms which may influence treatment response (differences in drug response based on
differences in clinical presentation within a psychiatric syndrome such as schizophrenia).
Personalized medicine and drug mechanisms
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The history of the concept of personalized medicine within pharmacology has been
reviewed in a prior article (2); therefore, it is only briefly summarized and updated here. At the
beginning of the 20th century, “chemical individuality” in drug response was hypothesized (3),
but it was not demonstrated until the 1950s when pharmacologists observed that some severe
adverse drug reactions (ADRs) only occurred in a small number of patients who were thought to
have peculiar genetic profiles. This led to the term “pharmacogenetics” (4). The Second World
War provided an impetus to drug development and the development of pharmacological
laboratories for better understanding drug response (5). For the next 20-30 years these
laboratories made progress in describing the pharmacokinetic and pharmacodynamic
mechanisms behind drug response (6). In the 1980s-90s the various genes associated with the
cytochrome P450 (CYP) isoenzymes were discovered, along with their genetic variations (7). In
the late 1990s, advances in genetics which allowed parallel genetic testing (testing for multiple
genes at the same time) by using the so-called DNA microarrays (8) led to pharmacogenomics,
the idea that many genes may influence drug response. The ability to test many genes led, in
1997, to Science defining “personalized prescription” as “tailoring drugs to a patient’s genetic
makeup” and to the prediction that personalized prescription would “soon” reach clinical practice
(9). The media, captivated by the race for the human genome, popularized the concepts of
personalized medicine and personalized prescription. After the race was over, it became clear
that factors other than genetics may be very important in drug response. Therefore, in the view of
the author (10), personalized prescription can be expressed as personalizing dosing and/or drug
selection and should include genetic as well as environmental (e.g., co-medications, herbal
medicines, smoking, foods, beverages) and personal (e.g., age, gender, ethnicity, illness)
variables in order to improve the safety and efficacy of psychopharmacological drugs. Moreover,
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psychiatry is increasingly combining new pharmacogenomic findings with therapeutic drug
monitoring (11), particularly to guide personalized dosing (12). In the opinion of the author, the
literature has not sufficiently recognized that each drug has its own pharmacokinetic and
pharmacodynamic mechanisms (13); therefore, “each drug is an individual.”
Personalized medicine and disease mechanisms
Further development of DNA microarray technology has allowed the testing of multiple
other products besides DNA, including proteins, RNAs, and lipids, and led to the development of
new diagnostic branches such as “protenomics”, “transcriptomics” and “metabonomics”. All of
these new techniques have resulted in a new concept in drug development, namely, the
biomarker. There are many definitions of biomarker, but Wagner proposed “a characteristic that
is objectively measured and evaluated as an indicator of normal biological processes, pathogenic
processes, or pharmacological response(s) to a therapeutic intervention” (14). There are different
types of biomarkers, including the pharmacogenomic biomarkers described above as the
pharmacokinetic and pharmacodynamic mechanisms behind drug response.
There has been a research boom in biomarkers in medicine both for practical and
theoretical reasons. From the practical point of view, biomarkers have been particularly
successful in oncology (15) for two reasons: 1) the cancerous tissue is available for study of the
pathogenetic mechanisms, and 2) our understanding of these pathogenetic mechanisms is
sufficiently developed to allow us to start selecting drugs according to the mechanisms in each
individual patient. From the theoretical point of view, there has been a revolution in
bioinformatics, including the development of a new scientific concept called “complexity” (16),
reflecting the complexity of scientific exploration when there are multiple influences causing a
phenomenon and the need exists for complex computer models to integrate all that is known
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about it. Complexity theory and its accompanying computer models are being introduced in
medicine by using the so-called “network” medicine (17). Therefore, personalized medicine
using disease mechanisms is becoming a fad in medicine.
If one is a psychiatrist who wants to think that psychiatry is not lagging behind other
medical disciplines, one should endorse the idea of using disease mechanisms to personalize
psychiatric treatment. As a matter of fact, many of the recent articles in psychiatric journals that
focus on the future of psychiatry propose using disease mechanism to personalize psychiatric
treatment, but these articles usually ignore the less glamorous drug response mechanisms
proposed by pharmacologists. There are many of these articles in many different journals but the
author can point out a few of them for the reader (18-22).
This author proposes that the path to personalized psychiatry which uses disease
mechanisms while forgetting drug response mechanisms is the wrong road. He acknowledges
that our knowledge of the use of pharmacokinetic and pharmacodynamic mechanisms for
personalizing psychiatric treatment is pretty limited since it applies to a few drugs, and more
fundamentally to pharmacokinetic mechanisms. Our understanding of pharmacodynamic
mechanisms of psychiatric drugs is too limited to have much clinical relevance (12, 23, 24).
Personalized medicine based on drug mechanisms is a “humble” pathway not likely to lead to
any major breakthroughs but could promote the use of currently available drugs in a better way.
It is not surprising that, if one wants to compete with cancer researchers in marketing and
funding, one should propose that psychiatry can cure mental illnesses (25) by personalizing
treatment (26), since oncology appears to be on the verge of curing many types of cancers. On
the other hand, the author proposes that at the current time, despite the wide endorsement of
psychiatric researchers of the disease mechanism to personalize psychiatry, it may be premature

8
and, furthermore, a waste of time and money. This is based on two ideas: 1) psychiatry is lagging
behind medicine and many of the psychiatric diseases, such as schizophrenia, are more
syndromes than diseases; and 2) even if one focuses on diseases with known brain
neuropathology, such as Alzheimer disease, the complexity of brain mechanisms currently
appears insurmountable.
The problem with the concept of disease in psychiatry
In a JAMA article in 2005, McHugh (27) pointed out that psychiatry is 150 years behind
medicine, so we are trying to do what 19th century physicians did. At that time, there was a
revolution characterized by the convergence of three ways of thinking, which have been called
anatomoclinical (relating signs and symptoms with disturbances in specific organs),
physiopathological (relating diseases or their symptoms/signs with disturbances in normal
physiology) and etiopathological (finding specific causes of some diseases and their lesions)
(28). This led to the revolutionary success of 20th century medicine.
The problems with the scientific approach in psychiatry have been discussed previously
by the author (29) but anyone with historical knowledge of psychiatric disease knows that
diseases such as schizophrenia (30) are at best syndromes and not medical diseases in the
traditional sense. Cancers, such as colon cancer, are being divided into different diseases based
on pathogenic mechanism. Unfortunately, psychiatry is far from reaching that point. Moreover,
we have no way of validating the diagnosis of most psychiatric disorders and establishing their
boundaries with other psychiatric disorders.
Problems dealing with brain complexity: Alzheimer disease
There is no doubt that originally Alzheimer disease was a psychiatric disease. In 1907,
Alzheimer, a psychiatrist, described the neuropathology in one case of presenile dementia with
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psychosis and in 1910 Kraepelin, a psychiatrist, (in the 8th edition of his textbook) baptized it as
a new illness (31). After including “senile” dementia cases within the boundaries of Alzheimer
disease, a major development in neuroscience research occurred in 1990; it included genetic
findings such as the association of Apolipoprotein E-4 with the age of onset of common lateonset Alzheimer disease.
It is now doubtful that Alzheimer disease can be called a psychiatric disease, since most
of the new findings come from neurologists and other neuroscientists. To demonstrate, the
author completed a PubMed search on 3/1/14 comparing articles from the last 10 years of two
pairs of similar journals in neurology and in psychiatry. Neurology was compared with the
American Journal of Psychiatry and JAMA Neurology (previously Archives of Neurology) with
JAMA Psychiatry (previously Archives of General Psychiatry). Neurology published 912 articles
on Alzheimer disease (or 8.2%, 912/11156) versus 54 (or 1.7%, 54/3428) in the American
Journal of Psychiatry. JAMA Neurology published 501 articles (or 16.8%, 501/2985) versus 48
(or 3.0%, 48/1560) in JAMA Psychiatry. In both absolute and relative terms, Alzheimer disease
is a major topic in neurological journals and a rather minor topic in psychiatric journals.
Let’s stretch reality and consider Alzheimer disease a psychiatric disease with known
neuropathology and clearly established boundaries, and a good example of a psychiatric disease
that follows the medical model, which is the ideal that Kraepelin proposed for psychiatric
diseases one hundred years ago (32). The problem is that 20 years of intensive research using the
disease mechanism has led to many strategies targeting different mechanisms but, unfortunately,
the outcome has been disappointing (33,34). Thus, the attempts of neuroscience to use disease
mechanisms to develop new treatments for Alzheimer’s are not working well; a personalized
treatment for Alzheimer disease would appear to be a fantasy due to the complexity of brain
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mechanisms. Therefore, even if we assume that Alzheimer disease is a psychiatric disease, the
lack of success of the mechanistic disease approach to it is not good news for psychiatry.
Alzheimer disease has 100 years of replicated neuropathological findings and 20 years of
mechanistic studies based on reasonable understanding of its genetics. If one compares that with
schizophrenia, for which Alzheimer completely failed as a neuropathologist, we find 100 years
of arguments about schizophrenia’s boundaries (30) and 60 years of treatment with drugs
discovered by serendipity, which are considered not to be specific treatment for schizophrenia
but are for all kinds of psychoses. In summary, even if major breakthroughs and ways of
validating schizophrenia diagnosis occur in coming decades, our experience with Alzheimer
disease tells us that our limited understanding of brain mechanisms is a major problem when
compared with the highly developed mechanistic discipline of oncology.
A forgotten way of personalizing treatment in psychiatry using clinical characteristics
The author has proposed that consideration of disease mechanisms may not currently be a
viable way of personalizing psychiatric treatment. However, past attempts to personalize
psychiatric treatments based on the clinical profile of the patient remain ignored by current
psychiatric researchers.
The idea behind these ignored approaches is that diseases, such as schizophrenia and
depression, are not diseases but syndromes that can be carved out by sophisticated use of clinical
symptoms in more specific diseases that can be better related to treatment response. These
approaches were heavily invested in descriptive psychopathology, which was supposed to be the
“language of psychiatry” (35) but interest in descriptive psychopathology has been decimated by
the changes in US psychiatry since the DSM-III (29,36).
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Ban has been one of the main traditional psychopharmacologists defending the concept
that a disease’s clinical profile can be used to group patients according to response (37, 38). He
has focused on depression and schizophrenia but for space reasons, this editorial will focus only
on schizophrenia. The current concept of schizophrenia presented in US nosological systems
since the DSM-III combines the ideas of Kraepelin, Bleuler and Schneider (30,39), but there is
another model of schizophrenia that is, for the most part, ignored in US psychiatric textbooks
and journals. As far as the author can tell, this alternative approach to diagnosing schizophrenia
has rarely been described in US journals; two were selected as representative: Journal of Clinical
Psychopharmacology and American Journal of Psychiatry. On 3/27/14, a PubMed search
produced 4624 articles from the Journal of Clinical Psychopharmacology, of which 873 were on
schizophrenia but none of them used this classification (adding the word “Leonhard” to the prior
schizophrenia search provided no articles). On 3/27/14, a PubMed search produced 23,589
articles from the American Journal of Psychiatry, of which 3731 were on schizophrenia but no
US articles used this classification. Only two articles (one letter to the editor and one twin
genetic study) by the same German research group were identified.
Wernicke, one of the Kraepelin’s main competitors, developed an alternative way of
classifying psychosis. This approach to psychosis is sometimes labeled the approach of the
Berlin school of psychiatry, since it was developed in Berlin. Wernicke trained Kleist, who
trained Leonhard, who presented the final version of this alternative model of classifying
psychosis. The Leonhard’s psychosis model has been totally eclipsed by the Kraepelinian model.
Wernicke died at a relatively early age in an accident (32). Most importantly, Leonhard worked
at a Berlin hospital that stayed on the Russian side of Berlin and his textbook was not translated
into English until recently (40). Leonhard was a very sophisticated clinician who did family and

12
twin studies in hundreds of patients. His two major accomplishments include: 1) his proposal for
the first time that familial history separates mono and bipolar depression, and 2) his theory that a
group of psychoses lie between schizophrenia and manic-depressive illness; he called them
cycloid psychoses (40). Leonhard proposed that schizophrenia is a syndrome including several
illnesses (40), some of which are genetic and others of which are not. Systematic schizophrenia
consists of non-genetic illnesses including paraphrenias, hebephrenias and catatonias.
Unsystematic schizophrenias are genetic illnesses including cataphasia, affect-laden paraphrenia
and periodic catatonia. Astrup (41), a Norwegian psychiatrist, conducted an important long-term
outcome study in schizophrenia patients. He initially studied 189 patients by applying
Leonhard’s classification. Fish (42) reclassified, with Astrup, another 285 chronic schizophrenia
patients. Finally, Fish included all 474 patients with schizophrenia in an article which reported
that <1/4 of systematic schizophrenia patients versus >4/5 of unsystematic schizophrenia patients
responded to first-generation antipsychotics (42). Later on, Guy et al. (43) in an international
survey of 768 patients with chronic schizophrenia, found that tardive dyskinesia was
overrepresented in patients with systematic versus those with unsystematic schizophrenia (13.3%
vs 4.3%). In a small group of 50 patients with chronic schizophrenia in Germany, Beckmann et
al. (44) proposed that the prognosis did not appear to change with antipsychotics when compared
with Leonhard’s observations. All of these outcome studies were conducted by sophisticated
clinicians who did not use blinding or placebo in their studies but suggested that systematic
schizophrenia does not respond well at least to first-generation antipsychotics. There is little
reason to think that these clinical researchers were biased toward finding greater response to
antipsychotics in unsystematic schizophrenia, since Leonhard developed his classification in the
pre-neuroleptic era.
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The author, along with Ban (37, 38), believes that schizophrenia and major depressive
disorder are syndromes rather than illnesses, but all of these pre-DSM-III attempts to divide them
into more homogenous subgroups that may predict treatment response remain forgotten. They
are not considered because they were conducted by sophisticated clinicians who did not use wellcontrolled designs with blinding and placebo. Due to these methodological weaknesses, these
studies remain forgotten by current psychopharmacologists who only value clinical trials using
well-controlled designs. Contemporary psychopharmacologists may have forgotten that
psychopharmacological drugs were discovered by sophisticated clinicians without using wellcontrolled designs. The use of well-controlled designs has not brought any revolutionary changes
in psychopharmacology, just some second-generations drugs with possibly some better ADR
profiles but of doubtful greater efficacy. The author thinks that it will be interesting to
incorporate some of these attempts to subdivide schizophrenia and major depression in future
well-controlled pragmatic studies of psychotropic drugs. Unfortunately, this will require
intensive clinical training of psychiatrists involved in the diagnosis and assessment of patients.
When psychiatrists are heavily invested in using biological mechanisms to personalize
psychiatric treatments, it may be too late to try to go back to forgotten attempts to personalize
treatment according to sophisticated clinical assessments.
Conclusions
Personalized medicine has finally been discussed in psychiatric journals but psychiatrists
have mainly focused on the promise of using disease mechanisms to personalize treatment.
Psychiatric disorders such as schizophrenia and depression are not diseases, in the medical sense,
and are probably more like syndromes. Moreover, even if one focuses on Alzheimer disease,
which is definitively closer to the concept of brain disease, current mechanistic approaches have
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been rather disappointing, and it is not clear that personalized prescription for treating Alzheimer
disease can take place in the next 1-2 decades.
Instead of spending much time and effort focusing on the mechanisms of diseases that
may be syndromes rather than diseases, the author believes that psychiatrists should 1) learn
more about personalizing prescription using the drug mechanisms that are common among
syndromes, and 2) reconsider prior attempts to use sophisticated clinical approaches that try to
subdivide psychiatric syndromes into groups that may be more homogenous for treatment
response. First, learning more about personalized prescription as understood by pharmacologists
may bring definitive but only modest improvements (12), either by using pharmacokinetic
mechanisms to personalize drug treatment with a few psychiatric drugs, or by considering some
pharmacodynamic mechanisms for personalizing drug selection for a few psychiatric drugs
(clinicians can rule out some patients through the use of HLA testing before prescribing
carbamazepine in East Asian patients). Second, increasing our knowledge of more sophisticated
clinical approaches of classification of psychiatric syndromes and introducing them in clinical
trials cannot be worse than the current situation in which pharmaceutical companies, after 3 or 4
decades, have failed to generate mechanistically new drugs and are abandoning psychiatry (45).
It is possible that more clinically homogenous subgroups of patients may be suitable for the
mechanistic approaches. For example, a genetic variant has been associated with one of
Leonhard’s diseases within the schizophrenia syndrome, periodic catatonia (46).
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